Elicio Therapeutics (Nasdaq: ELTX) granted an aggregate of 30,300 inducement stock options on February 17, 2026, to a newly hired employee under its 2024 Inducement Incentive Award Plan.
The options have an exercise price of $8.59 per share (Nasdaq close on Feb 17, 2026) and vest over four years with 25% vesting after one year and monthly vesting thereafter, subject to continued service.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – ELTX
+3.38%
1 alert
+3.38%News Effect
+$5MValuation Impact
$159MMarket Cap
0.0xRel. Volume
On the day this news was published, ELTX gained 3.38%, reflecting a moderate positive market reaction.
This price movement added approximately $5M to the company's valuation, bringing the market cap to $159M at that time.
Inducement options:30,300 optionsOption exercise price:$8.59 per shareVesting schedule:4 years; 25% after 1 year+5 more
8 metrics
Inducement options30,300 optionsGranted to a new employee on Feb 17, 2026
Option exercise price$8.59 per shareInducement grant strike, equal to Feb 17, 2026 close
Vesting schedule4 years; 25% after 1 yearInducement options vesting contingent on continued service
CEO stock options147,200 optionsGranted Feb 2, 2026 at $8.10 exercise price
CEO RSUs73,600 RSUsGranted Feb 2, 2026 at $0 grant price
Resale registration shares103,225 sharesCovered by S-3 resale registration for warrant holder
Q3 2025 net loss$10.1MNet loss for quarter ended Sept 30, 2025
Cash balance$20.6MCash and equivalents as of Sept 30, 2025
Market Reality Check
Price:$8.75Vol:Volume of 46,887 is relat...
low vol
$8.75Last Close
VolumeVolume of 46,887 is relatively light at a 0.32x multiple of the 20‑day average.low
TechnicalShares trade slightly below the 200-day MA of 8.8, suggesting a modestly weak longer-term trend into this filing.
Peers on Argus
ELTX was near flat (+0.47%) while momentum scanners flagged biotech peers CGTX a...
2 Up
ELTX was near flat (+0.47%) while momentum scanners flagged biotech peers CGTX and TRDA moving up without news, indicating this routine grant looks stock-specific rather than part of a sector rotation.
Q3 2025 results with narrowed net loss and AMPLIFY‑7P immunogenicity, DFS analysis timing.
Pattern Detected
ELTX has repeatedly announced inducement grants and executive/clinical updates with mixed but generally modest next-day price reactions, showing no consistent pattern of strong moves on similar routine news.
Recent Company History
Over the past few months, ELTX has mixed operational and financing developments. It reported multiple inducement option grants (Dec 15, 2025 and Jan 15, 2026) under the 2024 Inducement Plan, a key Phase 2 AMPLIFY‑7P antigen‑spreading update on Dec 11, 2025, and appointed a new CTO on Nov 19, 2025. Q3 2025 results on Nov 13, 2025 narrowed net loss to $10.1M with $20.6M cash. Today’s small inducement grant continues the pattern of incremental HR- and equity-related disclosures.
Regulatory & Risk Context
Active S-3 Shelf
Shelf Active
Active S-3 Shelf Registration
2025-11-13
An effective S-3 resale registration filed on Nov 13, 2025 covers up to 103,225 shares issuable from a warrant with a $7.75 exercise price and a 49.99% ownership cap. Proceeds from selling stockholder sales go to the holder, while the company only receives cash if the warrant is exercised.
Market Pulse Summary
This announcement details a routine HR-related equity grant of 30,300 inducement stock options at $8...
Analysis
This announcement details a routine HR-related equity grant of 30,300 inducement stock options at $8.59 under Nasdaq Listing Rule 5635(c)(4), vesting over four years. It follows a series of executive equity awards and prior inducement grants, indicating continued hiring and retention efforts. Investors may watch how these grants accumulate relative to total shares, alongside existing warrant-based resale capacity under the S-3 filing and the company’s previously disclosed cash and loss profile.
"granted an aggregate of 30,300 inducement stock options to a new employee"
Inducement stock options are grants of the company’s stock rights given to recruit or retain a specific executive or employee, often as a signing bonus instead of cash. Investors care because these awards can increase the total shares outstanding and dilute existing ownership, alter future reported expenses, and signal how the company is paying for talent; think of them as a hiring incentive paid in future company pieces rather than immediate money.
nasdaq listing rule 5635(c)(4)regulatory
"as an inducement material... in accordance with Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
restricted stock unitsfinancial
"received new equity awards in the form of restricted stock units and stock options"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
stock optionsfinancial
"granted an aggregate of 30,300 inducement stock options to a new employee"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
shelf registration statementregulatory
"[S-3] Elicio Therapeutics, Inc. Shelf Registration Statement"
A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.
senior secured convertible notefinancial
"converted a $20.0 million senior secured convertible note (plus $0.3 million interest)"
A senior secured convertible note is a loan a company takes that is backed by specific assets and has first claim on repayment ahead of other creditors, but can also be exchanged for company shares under agreed conditions. For investors it signals higher priority if the company struggles (like a mortgage holder vs a general creditor) while also creating potential stock dilution if the loan is converted into equity, affecting value and recovery prospects.
warrantfinancial
"issuable upon exercise of a warrant issued on June 3, 2025 to GKCC, LLC"
A warrant is a time-limited financial contract that gives its holder the right to buy a company's shares at a set price before a specified date, like a coupon that lets you purchase stock at a fixed discount for a limited time. It matters to investors because warrants offer leveraged exposure to a stock’s upside and can dilute existing shareholders if exercised, so they affect potential gains and the company’s outstanding share count.
schedule 13g/aregulatory
"[SCHEDULE 13G/A] Elicio Therapeutics, Inc. SEC Filing"
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.
AI-generated analysis. Not financial advice.
BOSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that on February 17, 2026, Elicio granted an aggregate of 30,300 inducement stock options to a new employee, as an inducement material to such individual entering into employment with Elicio in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement stock options were approved by the Compensation Committee of Elicio’s Board of Directors and granted under the Elicio Therapeutics, Inc. 2024 Inducement Incentive Award Plan.
The grant provides for the purchase of shares of Elicio common stock at a price of $8.59 per share, the closing price per share of Elicio common stock as reported by Nasdaq on February 17, 2026, the date of grant.
The grant vests over four years, with 25 percent of the shares vesting on the first anniversary of the employee’s start date, and the remainder vesting ratably at the end of each subsequent month thereafter, subject to such employee’s continued service relationship with Elicio through the applicable vesting dates.
About Elicio Therapeutics
Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of high-prevalence cancers, including mKRAS-positive pancreatic and colorectal cancers. Elicio intends to build on recent clinical successes in the personalized cancer immunotherapy space to develop effective, off-the-shelf immunotherapies. Elicio’s Amphiphile (“AMP”) technology aims to enhance the education, activation and amplification of cancer-specific T cells relative to conventional immunotherapy strategies, with the goal of promoting durable cancer immunosurveillance in patients. Elicio’s ELI-002 lead program is an off-the-shelf immunotherapy candidate targeting the most common KRAS mutations, which drives approximately 25% of all solid tumors. Off-the-shelf immunotherapy approaches have the potential benefits of low cost, rapid commercial scale manufacturing, and rapid availability of drug to patients especially in neo-adjuvant settings and for prophylaxis in high-risk patients, contrary to personalized immunotherapy approaches. ELI-002 is being studied in an ongoing, randomized clinical trial in patients with mKRAS-positive pancreatic cancer who completed standard therapy but remain at high risk of relapse. ELI-002 also has been studied in patients with mKRAS-positive colorectal cancer (“CRC”) in Phase 1 studies. The updated AMPLIFY-201 Phase 1 data for PDAC and CRC was presented at the ESMO Immuno-Oncology Congress 2024 and included a 16.3-month median recurrence-free survival and 28.9-month median overall survival for the full study population. In the future, Elicio plans to expand ELI-002 to other indications including mKRAS positive lung cancer and other mKRAS positive cancers. Elicio’s pipeline includes additional off-the-shelf therapeutic cancer immunotherapy candidates, including ELI-007 and ELI-008, that target BRAF-driven cancers and p53 hotspot mutations, respectively. For more information, please visit www.elicio.com.
Investor Relations Contact Brian Ritchie LifeSci Advisors (212) 915-2578 britchie@lifesciadvisors.com
FAQ
What did Elicio Therapeutics (ELTX) announce on February 18, 2026 about inducement grants?
Elicio announced an inducement grant of 30,300 stock options to a new employee on February 17, 2026. According to the company, options were approved by the Compensation Committee and issued under the 2024 Inducement Incentive Award Plan with a $8.59 per-share exercise price.
What is the exercise price and how was it determined for ELTX inducement options?
The exercise price is $8.59 per share, equal to Nasdaq closing price on Feb 17, 2026. According to the company, the strike matches the closing market price on the grant date, consistent with Nasdaq Listing Rule requirements.
How do the ELTX inducement options vest and when does vesting begin?
The options vest over four years with 25% vesting after one year, then monthly thereafter. According to the company, vesting is contingent on the employee's continued service through each vesting date.
Under what plan were the ELTX inducement options granted and who approved them?
The grant was made under the 2024 Inducement Incentive Award Plan and approved by the Compensation Committee. According to the company, the award complies with Nasdaq Listing Rule 5635(c)(4) for inducement grants.
Will the ELTX inducement grant immediately dilute existing shareholders?
The grant itself does not immediately dilute shareholders; dilution would occur only if options are exercised into shares. According to the company, 30,300 options were granted, and any dilution depends on future exercise and outstanding share count.
Why did Elicio use an inducement grant under Nasdaq Listing Rule 5635(c)(4)?
The company used an inducement grant to compensate a newly hired employee outside existing equity plans. According to the company, the grant was made in accordance with Nasdaq Listing Rule 5635(c)(4) allowing equity inducements for new hires.
